← All MEPs

Ivan David

European Parliament · ESN · 🇨🇿 Czechia

Term: since 18 July 2019

Participation in roll-call votes

93 % of the 2,540 roll-call votes held during their term: took part in the vote (for, against or abstention)

Participation month by month

0 % 50 % 100 % July 2019 : participation 100 % (1 / 1), presence 100 % (1 / 1) 2019 September 2019 : participation 100 % (5 / 5), presence 100 % (5 / 5) October 2019 : participation 95 % (18 / 19), presence 95 % (18 / 19) November 2019 : participation 100 % (18 / 18), presence 100 % (18 / 18) December 2019 : participation 100 % (6 / 6), presence 100 % (6 / 6) January 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) 2020 February 2020 : participation 88 % (7 / 8), presence 88 % (7 / 8) May 2020 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2020 : participation 100 % (12 / 12), presence 100 % (12 / 12) July 2020 : participation 100 % (19 / 19), presence 100 % (19 / 19) September 2020 : participation 67 % (16 / 24), presence 67 % (16 / 24) October 2020 : participation 100 % (37 / 37), presence 100 % (37 / 37) November 2020 : participation 100 % (32 / 32), presence 100 % (32 / 32) December 2020 : participation 100 % (30 / 30), presence 100 % (30 / 30) January 2021 : participation 96 % (22 / 23), presence 96 % (22 / 23) 2021 February 2021 : participation 100 % (21 / 21), presence 100 % (21 / 21) March 2021 : participation 58 % (18 / 31), presence 58 % (18 / 31) April 2021 : participation 100 % (81 / 81), presence 100 % (81 / 81) May 2021 : participation 100 % (26 / 26), presence 100 % (26 / 26) June 2021 : participation 69 % (20 / 29), presence 69 % (20 / 29) July 2021 : participation 100 % (27 / 27), presence 100 % (27 / 27) September 2021 : participation 100 % (19 / 19), presence 100 % (19 / 19) October 2021 : participation 100 % (42 / 42), presence 100 % (42 / 42) November 2021 : participation 70 % (19 / 27), presence 70 % (19 / 27) December 2021 : participation 100 % (29 / 29), presence 100 % (29 / 29) January 2022 : participation 100 % (7 / 7), presence 100 % (7 / 7) 2022 February 2022 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2022 : participation 49 % (18 / 37), presence 49 % (18 / 37) April 2022 : participation 100 % (22 / 22), presence 100 % (22 / 22) May 2022 : participation 100 % (88 / 88), presence 100 % (88 / 88) June 2022 : participation 52 % (24 / 46), presence 52 % (24 / 46) July 2022 : participation 97 % (30 / 31), presence 97 % (30 / 31) September 2022 : participation 100 % (25 / 25), presence 100 % (25 / 25) October 2022 : participation 100 % (32 / 32), presence 100 % (32 / 32) November 2022 : participation 92 % (35 / 38), presence 92 % (35 / 38) December 2022 : participation 100 % (18 / 18), presence 100 % (18 / 18) January 2023 : participation 100 % (16 / 16), presence 100 % (16 / 16) 2023 February 2023 : participation 100 % (29 / 29), presence 100 % (29 / 29) March 2023 : participation 76 % (22 / 29), presence 76 % (22 / 29) April 2023 : participation 100 % (24 / 24), presence 100 % (24 / 24) May 2023 : participation 100 % (93 / 93), presence 100 % (93 / 93) June 2023 : participation 100 % (40 / 40), presence 100 % (40 / 40) July 2023 : participation 98 % (39 / 40), presence 98 % (39 / 40) September 2023 : participation 100 % (27 / 27), presence 100 % (27 / 27) October 2023 : participation 98 % (39 / 40), presence 98 % (39 / 40) November 2023 : participation 74 % (39 / 53), presence 74 % (39 / 53) December 2023 : participation 100 % (40 / 40), presence 100 % (40 / 40) January 2024 : participation 86 % (42 / 49), presence 86 % (42 / 49) 2024 February 2024 : participation 100 % (63 / 63), presence 100 % (63 / 63) March 2024 : participation 96 % (48 / 50), presence 96 % (48 / 50) April 2024 : participation 97 % (207 / 213), presence 97 % (207 / 213) July 2024 : participation 100 % (1 / 1), presence 100 % (1 / 1) September 2024 : participation 100 % (8 / 8), presence 100 % (8 / 8) October 2024 : participation 100 % (13 / 13), presence 100 % (13 / 13) November 2024 : participation 96 % (26 / 27), presence 96 % (26 / 27) December 2024 : participation 100 % (18 / 18), presence 100 % (18 / 18) January 2025 : participation 100 % (6 / 6), presence 100 % (6 / 6) 2025 February 2025 : participation 100 % (10 / 10), presence 100 % (10 / 10) March 2025 : participation 100 % (14 / 14), presence 100 % (14 / 14) April 2025 : participation 95 % (21 / 22), presence 95 % (21 / 22) May 2025 : participation 100 % (54 / 54), presence 100 % (54 / 54) June 2025 : participation 100 % (22 / 22), presence 100 % (22 / 22) July 2025 : participation 100 % (32 / 32), presence 100 % (32 / 32) September 2025 : participation 100 % (29 / 29), presence 100 % (29 / 29) October 2025 : participation 100 % (45 / 45), presence 100 % (45 / 45) November 2025 : participation 73 % (37 / 51), presence 73 % (37 / 51) December 2025 : participation 100 % (31 / 31), presence 100 % (31 / 31) January 2026 : participation 100 % (22 / 22), presence 100 % (22 / 22) 2026 February 2026 : participation 96 % (27 / 28), presence 96 % (27 / 28) March 2026 : participation 98 % (43 / 44), presence 98 % (43 / 44) April 2026 : participation 100 % (51 / 51), presence 100 % (51 / 51) May 2026 : participation 60 % (15 / 25), presence 60 % (15 / 25) June 2026 : participation 86 % (30 / 35), presence 86 % (30 / 35) July 2026 : participation 100 % (35 / 35), presence 100 % (35 / 35) September 2026 : participation 85 % (34 / 40), presence 85 % (34 / 40) October 2026 : participation 79 % (42 / 53), presence 79 % (42 / 53) November 2026 : participation 100 % (13 / 13), presence 100 % (13 / 13)

Their votes

2,540 votes

DateTextResultTheir vote
Iran, in particular the case of 2012 Sakharov Prize Laureate Nasrin Sotoudeh Abstention
Forced labour and the situation of the Uyghurs in the Xinjiang Uyghur Autonomous Region Abstention
The Council Recommendation on vocational education and training (VET) for sustainable competitiveness, social fairness and resilience For
Sustainable corporate governance Abstention
A strong social Europe for Just Transition - Communication from the Commission Against
The European Citizens’ Initiative ‘Minority SafePack – one million signatures for diversity in Europe’ Abstention
Mechanisms for control by Member States of the Commission’s exercise of implementing powers: implementing acts at appeal committee level Against
The deteriorating situation of human rights in Egypt, in particular the case of the activists of the Egyptian Initiative for Personal Rights (EIPR) Abstention
The deteriorating situation of human rights in Egypt, in particular the case of the activists of the Egyptian Initiative for Personal Rights (EIPR) Abstention
Implementation report on the Return Directive Against
Implementation of the Dublin III Regulation Against
The Multiannual Financial Framework 2021-2027, the Interinstitutional Agreement, the EU Recovery Instrument and the Rule of Law Regulation Against
A new strategy for European SMEs Abstention
The EU Trade Policy Review Abstention
Resolution on the de facto ban on the right to abortion in Poland Against
Temporary measures in relation to value added tax for COVID-19 vaccines and in vitro diagnostic medical devices Against
Export of certain dual-use items from the EU to the United Kingdom For
Elimination of customs duties on certain products Against
Scalating tensions in Varosha following the illegal actions by Turkey and the urgent need for the resumption of talks Against
The continuous violations of human rights in Belarus, in particular the murder of Roman Bondarenko Abstention
The situation in Ethiopia For
The deteriorating situation of human rights in Algeria, in particular the case of journalist Khaled Drareni For
Situation of Fundamental Rights in the European Union - Annual Report for the years 2018-2019 Against
Stocktaking of European elections Against
The draft Commission implementing regulation approving carbendazim as an existing active substance for use in biocidal products of product-types 7 and 10 Against
Commission Implementing Regulation (EU) 2020/1511 of 16 October 2020 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances amidosulfuron, bifenox, chlorotoluron, clofentezine, clomazone, cypermethrin, daminozide, deltamethrin, dicamba, difenoconazole, diflufenican, fenoxaprop-P, fenpropidin, fludioxonil, flufenacet, fosthiazate… Against
Lead in gunshot in or around wetlands For
Application of Union tariff rate quotas and other import quotas Abstention
Improving development effectiveness and efficiency of aid Against
Foreign policy consequences of the COVID-19 outbreak Against
A New Industrial Strategy for Europe Against
Strengthening Media Freedom: the Protection of Journalists in Europe, Hate Speech, Disinformation and the Role of Platforms Against
Addressing product safety in the Single Market For
Towards a more sustainable single market for business and consumers For
Markets in financial instruments Against
Lead in gunshot in or around wetlands For
The impact of COVID-19 measures on democracy, the rule of law and fundamental rights Against
InvestEU Programme Against
Sustainable Europe Investment Plan - How to finance the Green Deal Against
Programme for the Union's action in the field of health for the period 2021-2027 (“EU4Health Programme”) Against

Rows per page: 20 40 100 200 All